Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2019-09-26 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
기타주요경영사항(자율공시)
Share Issue/Capital Change Classification · 98% confidence The document is a regulatory filing from Genome & Company regarding the conversion of Redeemable Convertible Preferred Shares (RCPS) into common stock. This involves a change in the company's capital structure and share count. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the appropriate category for announcements regarding new share issues or capital changes resulting from conversions.
2019-09-26 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding the results of a securities issuance (specifically, third-party allocated paid-in capital increase via convertible preferred shares). It details the number of shares issued, the total amount, and the payment date. This falls under the category of share issuance and capital changes.
2019-08-23 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement from Genome & Company. It details the issuance of convertible preferred shares via a third-party capital increase, including the number of shares, total amount, and payment date. This falls under the category of share issuance and capital changes.
2019-08-23 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회 결과' (Extraordinary General Meeting Results) and details the specific resolutions passed during the meeting, such as articles of incorporation amendments, stock option grants, and convertible preferred stock issuance. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2019-08-07 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting period. This type of disclosure regarding capital structure changes and employee compensation via stock options is classified as a share issue or capital change announcement.
2019-08-07 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision for a third-party paid-in capital increase (유상증자결정). This is a formal regulatory filing in Korea (DART system) detailing the issuance of new shares, the purpose of capital raising, and the specific terms of the third-party allocation. It falls under the category of share issuance and capital changes.
2019-08-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.